Noopept vs Semax
Both emerged from the Russian nootropic research programme, both target memory and attention via BDNF and NGF induction, and no entry for either was found in the electronic medicines compendium (emc) on 17 October 2026. The chief practical difference is delivery: Noopept is orally active, Semax requires intranasal administration.
Side-by-side
| Noopept | Semax | |
|---|---|---|
| Chemistry | Proline dipeptide ester (peptidomimetic) | Heptapeptide (true peptide) |
| Route | Oral | Intranasal |
| Onset of effect | Hours (acute), days (cumulative) | Hours (acute), days (cumulative) |
| Active species | Cycloprolylglycine (metabolite) + parent | Semax peptide |
| Mechanism | Glutamate modulation + BDNF/NGF induction | BDNF/NGF induction + enkephalinase + monoamine |
| Clinical use (Russia) | Approved for cognitive indications | Approved for cerebrovascular indications |
| UK status | No emc entry found (checked 17 October 2026) | No emc entry found (checked 17 October 2026) |
The choice usually comes down to route
Origin and development history
Two arms of the same Russian nootropic programme
Both compounds emerged from the sustained Russian nootropic research programme that ran through the 1980s-90s at the Institute of Molecular Genetics and adjacent Russian Academy of Sciences institutes. Semax was developed at the Institute of Molecular Genetics as a stable analogue of the ACTH(4-10) fragment, and is a registered Russian product (Vidal.ru) for cerebrovascular and cognitive-support indications. Noopept was developed at the same programme in the same period as an orally-active peptidomimetic cognitive-support compound with a distinctive proline-dipeptide-ester architecture, and is a separate registered Russian product (Vidal.ru) for cognitive-support indications.
Both compounds have substantial Russian clinical-experience bases, and both are listed on Vidal.ru as registered Russian products (its Semax page marks the product as dispensed by prescription). No entry for either was found in the electronic medicines compendium (emc) or on the EMA's list of centrally authorised medicines on 17 October 2026.
Mechanism dissection
BDNF/NGF induction convergence, distinct upstream angles
At the level of downstream neurotrophic effects, Noopept and Semax converge — both increase BDNF and NGF expression in hippocampal and cortical tissue in preclinical characterisation, providing the shared cognitive-plasticity mechanism substrate that motivates their overlapping research applications.
Upstream of this shared downstream angle, the mechanism-of-action framing diverges. Semax's upstream mechanism includes enkephalinase inhibition (extending endogenous enkephalin activity) and monoaminergic modulation (particularly dopaminergic and serotonergic effects). Noopept's upstream mechanism includes glutamate-system modulation (particularly AMPA and NMDA receptor effects) and the CPG (cycloprolylglycine) active metabolite pathway that provides the mechanism-of-action bridge between the parent ester and its downstream cognitive effects.
For research designs that need to isolate specific upstream mechanism contributions, the two compounds are distinct tools rather than substitutable. For research designs that need the shared downstream BDNF/NGF-induction endpoint, either compound is a viable research tool with route-of-administration as the primary practical selector.
Evidence-base comparison
Post-stroke Semax versus cognitive-support Noopept
Semax's strongest evidence-base is in post-stroke rehabilitation — the multicentre Russian trial programme covering acute ischaemic stroke and post-stroke recovery indications provides the strongest single-peptide clinical evidence base in the cognitive-peptide field. This positioning makes Semax the research-tool of choice for post-stroke recovery research designs and for research designs that need the strongest available clinical-context evidence base among the Russian cognitive peptides.
Noopept's strongest evidence base is in general cognitive-support and mild-cognitive-impairment contexts, with Russian clinical trials reporting cognitive-endpoint improvements in age-related cognitive decline populations. The evidence base is substantial but the specific post-stroke clinical-application depth of Semax is not matched. Noopept's advantage is the practical oral-administration route and the well-established over-the-counter cognitive-support market position in Russia.